Divalent antibody fragments

Details Divalent antibody fragments Divalent antibody fragments

1999-06-08

2011-11-29

Saunders, David A. (Department: 1644)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S136100, C424S179100, C424S809000, C530S387300, C530S391100, C530S866000

Reexamination Certificate

active

08067005

ABSTRACT:
Divalent antibody fragments are described, each of which has one or more interchain bridges containing a synthetic or naturally occurring polymer selected from a polyalkylene, polyakenylene, polyoxyalkylene or polysaccharide. Each bridge may be the residue of a homo- or heterobifunctional cross-linking reagent and serves to link two heavy chains in each antibody fragment via the sulphur atoms of cysteine residues present in the chains. Each fragment may be attached to one or more effector or reporter molecules, and is of use in therapy or diagnostics where it has markedly improved binding and/or pharmacokinetic properties when compared to other antibody fragments which have the same number and type of polymer molecules but in which the polymer molecules are randomly attached.

REFERENCES:
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5968009 (1999-10-01), Akita et al.
patent: 6025158 (2000-02-01), Gonzalez et al.
patent: 0 384624 (1990-08-01), None
patent: 0 392745 (1990-10-01), None
patent: 0 348442 (1993-01-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 89/01476 (1989-02-01), None
patent: WO 89/01974 (1989-03-01), None
patent: WO 90/09195 (1990-08-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/22583 (1992-12-01), None
patent: WO 93/06231 (1993-04-01), None
patent: WO 98/25971 (1998-06-01), None
patent: 85/8794 (1985-11-01), None
patent: 88/8127 (1988-10-01), None
patent: 90/2839 (1990-04-01), None
Abuchowski, A. et al.,J. Biol. Chem, “Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol ”,1977, 252,11, 3578-3581, “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase”,3582-3586.
Benhar, I. et al., “Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization”,Bioconjugate Chemistry, 1994, 5, 321-326.
Chiswell, D.J. et al., Phage antibodies: will new “coliclonal” antibodies replace monoclonal antibodies? ,J. Tibtech, 1992, 10, 80-84.
Delgado, C. et al., “Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification”,British. Journal of. Cancer, 1996, 73, 175-182.
Goodson, R.J.et al., “Site-directed pegylation of recombinant interleukin-2 at its glycosylation site”,Bio/Technology, 1990, 8, 343-346.
Hershfield, M.S. et al., “Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol”,P.N.A.S., 1991, 88, 7185-7189.
Kitamura, K. et al., “Chemical engineering of the monoclonal antibody A7 by polyethylene Glycol for targeting cancer chemotherapy”,Cancer Res. 1991, 51, 4310-4315.
Kramer, W. et al., “The gapped duplex DNA approach to oligonucleotide-directed mutation construction”,Nucl. Acids. Res. 1984, 12, 9441-9457.
Ling, T.G.I. et al., “A general study of the binding and Separation in partition affinity ligand assay. Immunoassay of β2- Microglobulin”,J. Immunol. Meth, 1983, 59, 327-337.
Lyons, A.et al., “Site-specific attachment to recombinant antibodies via introduced surface cysteine residues”,Protein Engineering., 1990, 3(8), 703-709.
Nucci, M. L. et al., “The therapeutic value of poly(ethylene glycol)-modified proteins”,Advanced . Drug Delivery Reviews, 1991, 6, 133-151.
Pedley, R.B. et al. “The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody”,Br. J. Cancer, 1994, 70, 1126-1130.
Stability of Protein Pharmaceuticals: in vivo Pathways of Degradation and Strategies for Protein Stabilization, 1991, 235-263, (Ahern, T.J. and Manning, M., eds. Plenum, N.Y.
Wilkinson, I, et al., “Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins”,Immunol. Letters, 1987, 15, 17-22.
Zalipsky, S. et al., “Use of functionalized ploy(Ethylene Glycol)s for modification of polypeptides”,Chemistry: Biotechnical and Biomedical Applications, 1992, 347-370.

Affiliated with

Also associated with

Rating

Divalent antibody fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Divalent antibody fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Divalent antibody fragments will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4307899